WP
PCVX icon

Woodline Partners’s Vaxcyte PCVX Stock Holding History

Woodline Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16M Hold
274,740
– – 0.06% 387
2025
Q4 		$12.7M Buy
274,740
+27,754
+11% +$1.24M 0.05% 406
2025
Q3 		$8.9M Buy
246,986
+46,908
+23% +$1.55M 0.04% 457
2025
Q2 		$6.5M Sell
200,078
-911,699
-82% -$29.9M 0.03% 513
2025
Q1 		$42M Sell
1,111,777
-9,145
-0.8% -$731K 0.27% 112
2024
Q4 		$91.8M Buy
1,120,922
+16,977
+2% +$1.69M 0.62% 20
2024
Q3 		$126M Buy
1,103,945
+397,042
+56% +$35.8M 1.06% 5
2024
Q2 		$53.4M Buy
706,903
+313,199
+80% +$21.3M 0.51% 51
2024
Q1 		$26.9M Buy
393,704
+353
+0.1% +$24.4K 0.25% 127
2023
Q4 		$24.7M Buy
393,351
+12,738
+3% +$662K 0.27% 116
2023
Q3 		$19.4M Sell
380,613
-9,843
-3% -$486K 0.23% 136
2023
Q2 		$19.5M Buy
390,456
+140,456
+56% +$6.66M 0.23% 130
2023
Q1 		$9.37M Hold
250,000
– – 0.13% 207
2022
Q4 		$12M Buy
250,000
+53,571
+27% +$2.1M 0.16% 176
2022
Q3 		$4.71M Sell
196,429
-269,895
-58% -$6.84M 0.07% 305
2022
Q2 		$10.1M Buy
+466,324
New +$10.8M 0.16% 173
2022
Q1 		– Sell
-97,396
Closed -$2.32M – 801
2021
Q4 		$2.32M Buy
+97,396
New +$2.27M 0.03% 401
2020
Q3 		– Sell
-23,026
Closed -$728K – 210
2020
Q2 		$728K Buy
+23,026
New +$740K 0.03% 142

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners's PCVX Position: Q1 2026 in Review

Woodline Partners held its Vaxcyte (PCVX) position steady in Q1 2026 at 274,740 shares worth $16M. The position accounts for 0.06% of the portfolio, ranked #387.

Woodline Partners first reported a position in PCVX in Q2 2020 and has held it in 18 quarters since. The position peaked at $126M in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Woodline Partners held 274,740 shares of Vaxcyte worth $16M as of Q1 2026.
  • Woodline Partners left its Vaxcyte share count unchanged in Q1 2026.
  • Vaxcyte made up 0.06% of Woodline Partners's portfolio in Q1 2026, its #387 holding.
  • Woodline Partners first reported a position in Vaxcyte in Q2 2020 and has held it in 18 quarters since.
  • Woodline Partners's Vaxcyte position peaked at $126M in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.